Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 4/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648528 | 0.84 | MAPK13 (0.40) | PTGS2CYP11B2CYP11B1RAB9AABL1 | |
| SCHEMBL6647985 | 0.76 | RAB9A (0.64) | PTGS2NPC1RAB9ACYP17A1 | |
| SCHEMBL3819167 | 0.73 | MAPK13 (0.42) | PTGS2CYP11B2CYP11B1RAB9AABL1 | |
| SCHEMBL3817004 | 0.73 | RPS6KA3 (0.41) | PTGS2CYP11B2CYP11B1NPC1RAB9A | |
| SCHEMBL19702700 | 0.68 | RPS6KA3 (0.49) | PTGS2CYP11B2CYP11B1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL19691723 | 0.67 | RPS6KA3 (0.48) | PTGS2CYP11B2CYP11B1NPC1RAB9A | |
| SCHEMBL6715107 | 0.65 | CYP11B2 (0.36) | CYP11B2CYP11B1ABL1CYP17A1PDE10A | |
| SCHEMBL30494467 | 0.65 | RPS6KA3 (0.52) | PTGS2CYP11B2CYP11B1RPS6KA3ABL1 | |
| SCHEMBL10273624 | 0.65 | ABL1 (0.55) | PTGS2CYP11B2CYP11B1RPS6KA3ABL1 | |
| SCHEMBL30494331 | 0.65 | CYP11B2 (0.50) | PTGS2CYP11B2CYP11B1SLC22A12RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040267017-A1 | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| EP-1490361-A1 | POLYCYCLIC COMPOUNDS AS POTENT ALPHA2-ADRENOCEPTOR ANTAGONISTS | ORION CORPORATION (FI) | 2004-12-29 | — | — | EP | disclosed |
| EP-1432706-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003082866-A1 | POLYCYCLIC COMPOUNDS AS POTENT ALPHA2-ADRENOCEPTOR ANTAGONISTS | ORION CORPORATION (FI) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003027085-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267017-A1 | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors | CYP17A1, CYP21A2, HSD17B1 | PTGS2 988/4885CYP11B2 45/4885CYP11B1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.